Status:
COMPLETED
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsors:
Novo Nordisk A/S
Conditions:
Type I Diabetes
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The trial is a placebo-controlled, double-blinded within cohorts, randomized, multiple ascending dose trial with a sequential trial design. The primary outcome is to investigate the safety and tolerab...
Detailed Description
A total of 48 patients with T1D are planned to be studied in 4 cohorts of 12 patients (9 on active and 3 on placebo treatment). Within each cohort, sentinel enrollment will occur and safety assessment...
Eligibility Criteria
Inclusion
- Willing to provide Informed Consent
- Participants must live in a location with rapid access to emergency medical services
- Age 18-45 years (both inclusive) at the time of signing informed consent
- Must have a diagnosis of T1D for less than 48 months at randomization
- Must have at least one diabetes-related autoantibody present (GAD65A; mIAA, if obtained within 10 days of the onset of insulin therapy; IA-2A; ICA; or ZnT8A)
- Must have stimulated C-peptide levels greater than or equal to 0.2 pmol/ml measured during an MMTT conducted at least 21 days from diagnosis of diabetes and within one month (37 days) of randomization
- Be willing to comply with intensive diabetes management
- HbA1c ≤8.5% at screening
- Subjects who are CMV and/or EBV seronegative at screening must be CMV and/or EBV PCR negative within 37 days of randomization and may not have had signs or symptoms of a CMV and/or EBV compatible illness lasting longer than 7 days within 37 days of randomization
- Be up to date on recommended immunizations
- Be at least 6 weeks from last live immunization
- Be at least 4 weeks from killed vaccine other than flu vaccine
- Participants are required to receive killed influenza vaccination at least 2 weeks prior to randomization when vaccine for the current or upcoming flu season is available
- Be willing and medically acceptable to postpone live vaccines during the treatment period and for 3 months following last dose of study drug
- If participant is female with reproductive potential, she must have a negative pregnancy test at screening and be willing to avoid pregnancy using a highly effective contraceptive method for the 12 months of the study
- Males of reproductive age must use adequate contraceptive method during the treatment phase and for 3 months following last dose of study drug
- Participants are required to receive an authorized non-live COVID-19 vaccination and be fully vaccinated, including eligible boosters as indicated, at least two weeks prior to randomization.
Exclusion
- Potential participants must not meet any of the following exclusion criteria:
- One or more screening laboratory values as stated
- Leukocytes \< 3,000/μL
- Neutrophils \<1,500 /μL
- Lymphocytes \<800 /μL
- Platelets \<100,000 /μL
- Haemoglobin \<6.2 mmol/L (10.0 g/dL)
- Potassium \>5.5 mmol/L or \<3.0 mmol/L
- Sodium \>150mmol/L or \< 130mmol/L
- AST or ALT ≥2.5 times the upper limits of normal
- Bilirubin ≥ 1.5 times upper limit of normal
- Glomerular Filtration Rate (eGFR) value of eGFR \< 60 ml/min/1.73 m2 as defined by KDIGO 2012 (43)
- Any other laboratory abnormality that might, in the judgment of the investigator, place the subject at unacceptable risk for participation in this trial
- Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within prior 7 days of screening
- Use of other immunosuppressive agents including chronic use of systemic steroids. Topical products are acceptable (nasal, conjunctival, skin)
- Have active signs or symptoms of acute infection at the time of randomization
- Have current, confirmed COVID-19 infection
- Chronic active infection other than localized skin infections
- Have evidence of prior or current tuberculosis infection as assessed by PPD, interferon gamma release assay or by history
- Have evidence of current or past HIV, Hepatitis B infection
- Have evidence of active Hepatitis C infection
- Vaccination with a live virus within the last 6 weeks and killed vaccine within 4 weeks (except 2 weeks for flu vaccine)
- Be currently pregnant or lactating, or anticipate getting pregnant within the one-year study period.
- Have severe obesity: adults BMI ≥ 40
- Have a history of malignancies
- Untreated hypothyroidism or active Graves' disease
- History of severe reaction to prior vaccination
- Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days after last blood draw (or 5 half-lives of investigational drug, whichever is greater) before screening, or currently enrolled in any other clinical trial
- Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the trial
- Supine blood pressure at screening outside the range of 90-139 mmHg for systolic or 50-89 mmHg for diastolic. To exclude white-coat nervousness a single repeat measurement is allowed
- Have any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk
- Any condition that in the investigator's opinion may adversely affect study participation or may compromise the study results
Key Trial Info
Start Date :
November 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 24 2024
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT04279613
Start Date
November 23 2020
End Date
April 24 2024
Last Update
May 20 2025
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Orange County
Orange, California, United States, 92868
2
University of California - San Francisco
San Francisco, California, United States, 94143
3
Stanford University
Stanford, California, United States, 94305
4
Barbara Davis Center at University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States, 80045